Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders

Sanjiv Gupta
Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur, India

Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia. Relevant literature since 2003 is reviewed. The effectiveness of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol and other atherogenic lipid fractions was studied in various Phase 2 and Phase 3 trials of Alirocumab, Evolocumab, and Bococizumab. The results of published long-term ODYSSEY and OSLER studies are summarized. There have been three excellent meta-analysis studies on PCSK9 inhibitors which are outlined. The complex problem of cost-effectiveness was carefully evaluated by the Institute for Clinical and Economic Review (ICER). The draft report (ICER-2015) is summarized herewith. The cardiovascular outcome trials with Evolocumab (FOURIER), Alirocumab (ODYSSEY OUTCOME) and Bococizumab (SPIRE-1 and SPIRE-2) are the ongoing clinical trials, and their results are expected in 2017–2018. The search for new cost-effective analogs of PCSK9 inhibitors is ongoing.

Keywords: PCSK9, LDLc, ASCVD

Abbreviations

ACC American College of Cardiology
AHA American Heart Association
Apo-A apolipoprotein A
Apo-B apolipoprotein B
ASCVD atherosclerotic cardiovascular disease
CI confidence interval
CTT cholesterol treatment trialist
CV cardiovascular
CVOTs cardiovascular outcome trials
ELISA enzyme-linked immunosorbent assay
FDA US Food and Drug Administration
FH familial hypercholesterolemia
HDLc high-density lipoprotein cholesterol
HeFH heterozygous familial hypercholesterolemia
HoFH homozygous familial hypercholesterolemia
ICER Institute for Clinical and Economic Review
LDL low-density lipoprotein
The cholesterol treatment in controlling LDLc in a meta-analysis of 170,000 participants in 26 randomized trials confirmed the efficacy and safety of intensive statin therapy in patients with ASCVD. The ideal principles “treat to target” and “lower the better and physiologically normal” have been advocated. An LDLc level of 50–70 mg/dL is considered ideal and optimal. Statins remain the most effective and validated therapy to lower LDLc (PROVE IT TIMI-22 trial). CTT Collaboration confirmed the efficacy and safety of intensive statin therapy in controlling LDLc in a meta-analysis of 170,000 participants in 26 randomized trials. The cholesterol treatment guidelines of the ACC and AHA in collaboration with the National Heart, Lung and Blood Institute have stressed the efficacy of statins in treating the following patients: 1) individuals with an established ASCVD, 2) individuals with primary LDLc ≥190 mg/dL, 3) diabetics aged 40–75 years with LDL ≥70 mg/dL, and 4) other individuals with a high estimated lifetime CV disease risk of ≥7.5%. The 2013 ACC/AHA guidelines on cholesterol treatment have not recommended any specific LDL target. Current guidelines in Europe and Canada advocate an LDLc target (<70 mg/dL) or a 50% reduction in LDLc. There is however a great variation in the response to intensive statin therapy, and additional therapy may be required to meet LDLc targets. IMPROVE-IT has recently concluded that addition of ezetimibe to statin therapy produces further reduction of LDLc with better CV results. However, under the circumstances of insufficient response to statin or statin intolerance, an alternative lipid-lowering drug may be required. PCSK9 inhibitors are recent additions to statins (and ezetimibe) as potent lipid-lowering drugs for the treatment of elevated LDLc and ASCVD.

**Objectives**

The aim of this paper was to describe the mechanism of action of monoclonal antibodies, which are powerful PCSK9 inhibitors, and their effects on the lipids studied in various clinical research studies. Studies on their safety and adverse effects were searched. Long-term trial effects, cost-effectiveness, present indications, future perspectives and CVOTs on PCSK9 inhibitors have been outlined.

**Methods**

Recent literature on PCSK9 inhibitors was searched. The PubMed and Embase databases and recent conferences held in 2014, 2015 and 2016 were searched. Various RCTs and three available meta-analysis studies were evaluated. The efficacy data included the effects on lipids and clinical outcomes as well as adverse effects.

**Results**

**Mechanism of action of PCSK9 inhibitors**

PCSK9 was discovered in 2001, and its gene was characterized in 2003. PCSK9 is initially secreted as an inactive enzyme precursor which undergoes intramolecular autocatalytic cleavage in the endoplasmic reticulum for activation. The matured PCSK9 moves out of the endoplasmic reticulum of the hepatic cells to be further handled by the Golgi apparatus of hepatic cells before entering the circulation.

The preferential pathway through which LDLc is normally cleared from the blood is its binding with LDL(R)s on the surface of liver cells. LDL(R) is a mosaic protein of 839 amino acids which mediates endocytosis of LDLc into the liver cells. The bound LDLc/LDL(R) complex is internalized into the liver cells where LDLc is further metabolized, while the LDL(R) recirculates back to the surface of liver cells for further interaction with LDLc. This process continues for several cycles (up to 150 cycles).

PCSK9 is an inhibitor of LDL(R). PCSK9 binds with LDL(R) on the surface of the liver cells and escorts it to the lysosomal system of liver cells for the destruction of LDL(R), which thus cannot return back to the surface of liver cells. The net result is a decrease in the population of LDL(R). Hence, less number of LDL(R)s are available at the liver cell surface to mop up LDLc for further metabolism.

PCSK9 and LDL(R) are secreted by hepatocytes. Their intracellular itenares appear similar, but their pathways
dive at the surface of liver cells. PCSK9 is secreted into the plasma, while LDL(R) remains at the surface of liver cells. Circulating PCSK9 binds with LDL(R) on the liver cell surface and interferes with the recycling back of LDL(R) after internalization with LDL and directs LDL(R) to the lysosomes for its destruction. PCSK9 and LDL(R) are coordinately regulated by SREBP2. PCSK9 thus regulates the expression and degradation of LDL(R).

PCSK9 inhibitors inhibit the binding of PCSK9 with LDL(R) and prevent degradation of LDL(R) which is available to bind LDLc for its further metabolism. It was observed that a rare “gain in function” by gene mutation of PCSK9 led to severe elevation of LDLc and premature ASCVD.14 On the reverse, a rare “loss of function” of PCSK9 was associated with significantly lower LDLc. These mutation researches favored active research to the development of PCSK9 inhibitors as therapeutic measure to lower LDLc. Elevated plasma levels of PCSK9 have been reported in FH and also in some patients with non-FH and during statin therapy. Inhibition of PCSK9 is therapeutically beneficial in lowering LDLc, since elevated plasma PCSK9 is equally detrimental in patients with FH and non-FH irrespective of defect in LDL(R).17

PCSK9 circulates in plasma as mature and furin-cleaved forms. Total plasma PCSK9 is measured by ELISA incorporating a polyclonal antibody against human PCSK9. Normal mean plasma level of total PCSK9 is 99.3±31 ng/mL. LDL apheresis in FH removes mature as well as furin-cleaved forms of PCSK9. About 40% of intact PCSK9 is found in association with LDLc. Most of the furin-cleaved forms are in the Apo-B-free fraction. About 25% of PCSK9 is associated with Lp (a) in plasma.

Lp (a) is a highly atherogenic LDL(c)-like particle characterized by the presence of Apo-A which is covalently bound to Apo-B. Analysis of Lp (a) fraction by ultracentrifugation, immunoprecipitation and ELISA quantification has shown a strong physical association between Lp (a) and PCSK9 in plasma. Lp (a) levels are genetically determined. The desirable plasma Lp (a) level is <14 mg/dL (<3.5 mmol/L). Lp (a) levels >50 mg/dL are associated with atherosclerosis and are refractory to lifestyle interventions. Current therapeutic options to reduce Lp (a) are limited to Niacin and PCSK9 inhibitors. However, the mechanism of interaction between Lp (a) and PCSK9 is not clearly known.

Monoclonal antibodies and development of PCSK9 inhibitors
Monoclonal antibodies are potent antilipid drugs which inhibit PCSK9. Three monoclonal antibodies have undergone extensive trials for their efficacy and safety. These are as follows: Praluent® (Alirocumab; REGN 727): manufactured by Regeneron (Tarrytown, NY, USA)/Sanofi Aventis (Paris, France); Rapatha® (Evolocumab; AMBG 1451): manufactured by Amgen ( Thousand Oaks, CA, USA); and Bococizumab (RN 316): developed by Pfizer (New York, NY, USA).

Alirocumab and Evolocumab have been the front-runners of PCSK9 inhibitors recognized by the FDA and European Medicines Agency.

Alirocumab was approved by the FDA on 24 July 2015 to be used in addition to diet and maximally tolerated statin therapy in adults with HeFH or patients with existing clinical ASCVD such as heart attack or stroke who require additional lowering of LDLc. The cost of Alirocumab in the USA is $14,600 per year.

Evolocumab was approved by the FDA on 27 August 2015 to be used in addition to diet and maximally tolerable statin therapy in adults with HeFH and HoFH or patients with clinical ASCVD such as heart attack or stroke who require additional lowering of LDLc. The cost of Evolocumab in the USA is $14,100 per year.

Bococizumab developed by Pfizer is under consideration for the FDA approval. Bococizumab has undergone Phase 2 trial. Ongoing Phase 3 trials include SPIRE (Studies of PCSK9 Inhibition and the Reduction of cardiovascular Events)-SI, SPIRE-HR and SPIRE-LDL (each 12-week trial). SPIRE-1 and SPIRE-2 are long-term CVOTs. Trials are being conducted simultaneously in the UK, the USA, and Europe.

All monoclonal antibodies are administered by subcutaneous route. Their standard doses are summarized in Table 1.

### Statins vs monoclonal antibodies
Statins have been the mainstay of treatment of elevated LDC. They lower LDLc by inhibiting the enzyme HMG-CoA reductase which has a vital role in the synthesis of cholesterol in the liver. In addition, statins enhance the expression of LDL(R) (as well as of PCSK9). Statin typically reduces LDLc by 30–40% (depending upon the dose of statin), but absolute value of LDLc rarely falls <60 mg/dL.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Once in 2 weeks (mg)</th>
<th>Once in 4 weeks (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alirocumab</td>
<td>75–150</td>
<td>300</td>
</tr>
<tr>
<td>Evolocumab</td>
<td>140</td>
<td>420</td>
</tr>
<tr>
<td>Bococizumab*</td>
<td>75/150</td>
<td>300</td>
</tr>
</tbody>
</table>

**Note:** *Dose may be reduced if LDlc is <25 mg/dL.
**Abbreviation:** LDlc, low-density lipoprotein cholesterol.

---

**Dovepress**

**Vascular Health and Risk Management**

Submit your manuscript | www.dovepress.com

423

For personal use only.
Monoclonal antibodies inhibit PCSK9 and prevent destruction of LDL(R). These are able to reduce LDLc to 25–40 mg/dL (50–75% reduction) and are more potent and effective than statins and ezetimibe.

Clinical trials and efficacy studies
Many clinical trials with PCSK9 monoclonal antibodies have demonstrated excellent efficacy and safety in a variety of patients including those with FH, non-FH, ASCVD, elevated CV risk and statin intolerance. The clinical trials have been classified as Phase 1, Phase 2 and Phase 3 trials. Some of the prominent trials are summarized in Tables 2–4. The reductions in LDLc vs placebo/statin/ezetimibe have ranged 45–70%. In addition, there has been reduction in total cholesterol (26–38%), Apo-B (34–52%), triglyceride (12–26%) and Lp (a) (15–31%). There has been a marginal nonsignificant increase in HDLc (2–8%).

Phase 2 trials
All three monoclonal antibodies have been evaluated in Phase 2 trials (Table 2). Evolocumab has undergone trials such as LAPLACE-TIMI 56, MENDEL-1, GAUSS, TESLA-A and RUTHERFORD. Each trial was of 12 weeks. Details of patient selection and the results are summarized in Table 2. There was reduction of LDLc by 41–66%. In HoFH, the LDL reduction was related to the presence/absence of LDL(R). There was no response in LDL(R)-negative patients and partial response in LDL(R)-defective patients. There was good response to Evolocumab in statin-intolerant patients (GAUSS trial).

Alirocumab has been investigated in ROTH study, Stein study and McKenney study. LDLc reduced by 31–72% in various studies. Both Alirocumab and Evolocumab also significantly reduced Apo-B, total cholesterol, triglyceride and non-HDLc. There were no clear drug-related toxicity reactions during 12-week study period.

Bococizumab is a humanized monoclonal antibody which binds with PCSK9 and reduces LDLc in patients with hypercholesterolemia. Ballantyne et al published results of Bococizumab in a Phase 2 trial of 24 weeks. It was a multicenter, double-blind, placebo-controlled, dose-ranging study in 354 patients on stable statin therapy with LDLc ≥80 mg/dL. The patients were randomized to 14- or 28-day treatment regime. In the 14-day regime, the patients were administered

Table 2 Phase 2 trials

<table>
<thead>
<tr>
<th>Trial/study</th>
<th>Reference</th>
<th>Patients</th>
<th>Duration of trial</th>
<th>PCSK9 inhibitor</th>
<th>Results: reduction in LDLc</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAPLACE-TIMI 56</td>
<td>Giugliano et al20</td>
<td>631</td>
<td>12 weeks</td>
<td>Evolocumab</td>
<td>41.8–66.1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc ≥100 mg/dL On statin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MENDEL-1</td>
<td>Koren et al21</td>
<td>406</td>
<td>12 weeks</td>
<td>Evolocumab</td>
<td>43.0–50.9% (depending on dose of Evolocumab)</td>
</tr>
<tr>
<td>GAUSS</td>
<td>Sullivan et al22</td>
<td>160</td>
<td>12 weeks</td>
<td>Evolocumab</td>
<td>43–63%</td>
</tr>
<tr>
<td>TESLA-A</td>
<td>Stein et al23</td>
<td>HoFH 8</td>
<td>12 weeks</td>
<td>Evolocumab</td>
<td>LDL(R)-negative: no response (2) LDL(R)-positive but defective (6) 19–26%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc ≥130 mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RUTHERFORD</td>
<td>Raal et al24</td>
<td>169</td>
<td>12 weeks</td>
<td>Evolocumab</td>
<td>44–56%</td>
</tr>
<tr>
<td>ROTH</td>
<td>Roth et al25</td>
<td>92</td>
<td>16 weeks</td>
<td>Alirocumab</td>
<td>73.5±3.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc &gt;100 mg/dL On atorvastatin 80 mg/day</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEIN</td>
<td>Stein et al26</td>
<td>HeFH: 77</td>
<td>12 weeks</td>
<td>Alirocumab</td>
<td>31.4–67.9% (depending upon dose of Alirocumab)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc &gt;100 mg/dL On statin ± ezetimibe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McKENNEY</td>
<td>McKenney et al27</td>
<td>183</td>
<td>12 weeks</td>
<td>Alirocumab</td>
<td>43–72% (mean=57%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc ≥100 mg/dL On statins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALLANTYNE</td>
<td>Ballantyne et al28</td>
<td>351</td>
<td>24 weeks</td>
<td>Bococizumab</td>
<td>28–53%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc &lt;80 mg/dL On statins</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PCSK9, proprotein convertase subtilisin/kexin type 9; LDLc, low-density lipoprotein cholesterol; HoFH, homozygous familial hypercholesterolemia; LDL(R), low-density lipoprotein receptor; TG, triglyceride; HeFH, heterozygous familial hypercholesterolemia.
Table 3  Phase 3 trials (with Evolocumab)

<table>
<thead>
<tr>
<th>Trial/study</th>
<th>Reference</th>
<th>Patients</th>
<th>Duration of trial</th>
<th>Mode of administration of Evolocumab</th>
<th>Results: reduction in LDLc</th>
</tr>
</thead>
<tbody>
<tr>
<td>MENDEL-2</td>
<td>Koren et al29</td>
<td>614</td>
<td>12 weeks</td>
<td>Biweekly or monthly</td>
<td>Compared with placebo: 52–57%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Compared with ezetimibe 38–40% (P&lt;0.001)</td>
</tr>
<tr>
<td>GAUSS-2</td>
<td>Stroes et al30</td>
<td>307</td>
<td>12 weeks</td>
<td>Biweekly or monthly</td>
<td>Compared with placebo 53–56%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Compared with ezetimibe 37–39% (P&lt;0.001)</td>
</tr>
<tr>
<td>OSLER-2</td>
<td>Koren et al31</td>
<td>1,104</td>
<td>52 weeks</td>
<td>Monthly</td>
<td>52.3% (mean) (P&lt;0.0001)</td>
</tr>
<tr>
<td>TESLA-B</td>
<td>Raal et al32</td>
<td>49</td>
<td>12 weeks</td>
<td>Monthly</td>
<td>30.9% (P&lt;0.0001)</td>
</tr>
<tr>
<td>LAPLACE-2</td>
<td>Robinson et al32</td>
<td>2,067</td>
<td>12 weeks</td>
<td>Biweekly or monthly</td>
<td>High statin: 68.3–76%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate statin: 68.2–71.4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ezetimibe: 38.2–47.2%</td>
</tr>
<tr>
<td>DESCARTES</td>
<td>Bloom et al34</td>
<td>901</td>
<td>52 weeks</td>
<td>Monthly</td>
<td>57.5% (at 12 weeks)</td>
</tr>
<tr>
<td>RUHTERFORD-2</td>
<td>Raal et al35</td>
<td>331 (HeFH)</td>
<td>12 weeks</td>
<td>Biweekly or monthly</td>
<td>Biweekly: 59.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDLc ≥100 mg/dl</td>
<td></td>
<td></td>
<td>Monthly: 61.3%</td>
</tr>
</tbody>
</table>

Abbreviations: LDLc, low-density lipoprotein cholesterol; LDL, low-density lipoprotein; TG, triglyceride; HeFH, heterozygous familial hypercholesterolemia.

Table 4  Phase 3 trials (with Alirocumab)

<table>
<thead>
<tr>
<th>Trial/study</th>
<th>Reference</th>
<th>Patients</th>
<th>Duration of trial</th>
<th>Drug (SC)</th>
<th>Results: reduction in LDLc</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODYSSSEY LONG TERM</td>
<td>Robinson et al36</td>
<td>2,341</td>
<td>52 weeks</td>
<td>70–150 mg biweekly</td>
<td>61.3% at 52 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Very high CV risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Included HeFH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maximally tolerated dose of statin</td>
</tr>
<tr>
<td>ODYSSSEY CHOICE II</td>
<td>Ongoing trial</td>
<td>200</td>
<td>24 weeks</td>
<td>300 mg monthly</td>
<td>Ongoing trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Uncontrolled on nonstatin lipids-lowering drugs (HeFH and non-FH)</td>
</tr>
<tr>
<td>ODYSSSEY COMBO II</td>
<td>Cannon et al37</td>
<td>720</td>
<td>12 weeks</td>
<td>75–150 mg biweekly</td>
<td>30% (P&lt;0.0001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>On maximally tolerated statin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>On ezetimibe</td>
</tr>
<tr>
<td>ODYSSSEY FH</td>
<td>Kastelein et al38</td>
<td>249</td>
<td>24 weeks</td>
<td>75–150 mg biweekly</td>
<td>49% (P&lt;0.0001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HeFH</td>
</tr>
<tr>
<td>ODYSSSEY ALTERNATIVE</td>
<td>Moriarty et al39</td>
<td>314</td>
<td>12 weeks</td>
<td>75–150 mg biweekly</td>
<td>Ongoing trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Statin intolerance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>On ezetimibe</td>
</tr>
<tr>
<td>ODYSSSEY MONO</td>
<td>Roth et al40</td>
<td>103</td>
<td>24 weeks</td>
<td>75 mg biweekly</td>
<td>32%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LDL 100–190 mg/dl</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No lipid-lowering drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High CV risk</td>
</tr>
</tbody>
</table>

Abbreviations: SC, subcutaneous; LDLc, low-density lipoprotein cholesterol; CV, cardiovascular; HeFH, heterozygous familial hypercholesterolemia; FH, familial hypercholesterolemia; LDL, low-density lipoprotein.

placebo (n=50) or Bococizumab once in 2 weeks at a dose of 50 (n=50), 100 (n=52) and 150 mg (n=50). In the 28-day regime, the patients received placebo (n=51) or Bococizumab at doses of 200 (n=50) or 300 mg (n=51). Compared with placebo, Bococizumab 150 mg Q 14 days reduced LDLc at week 12 by 53.4 mg/dL, and Bococizumab 300 mg Q 28 days reduced LDLc by 44.9 mg/dL. The dose of Bococizumab was reduced if LDLc was <25 mg/dL, and this threshold
was achieved frequently. Adverse events were almost similar across placebo and Bococizumab groups. Seven patients (2%) discontinued treatment. Most frequent adverse events were nasopharyngitis, diarrhea, bronchitis, arthralgia and injection-site reactions.

Phase 3 trials
Evolocumab has been evaluated in MENDEL-2,29 GAUSS-2,30 OSLER-2,31 TESLA-B,32 LAPLACE-2,33 DESCARTES34 and RUTHERFORD-2.35 DESCARTES34 and OSLER-231 have been long-term trials lasting 52 weeks. The characteristics of patients and trials are depicted in Table 3. There was a consistent reduction in LDLc by over 50% in most trials. The adverse reactions included injection-site reactions, mild neurocognitive impairment of memory and anemia.

Alirocumab has undergone Phase 3 trials such as ODYSSEY LONG TERM,36 ODYSSEY COMBO II,37 ODYSSEY FH,38 ODYSSEY ALTERNATE39 and ODYSSEY MONO,40 each lasting 12–24 weeks. The details of the trials are shown in Table 4.

Phase 3 trials with Bococizumab consist of SPIRE which is an extensive research program carried out to study Bococizumab under various conditions. The trials include SPIRE-SI, SPIRE-AI (Auto Injector), SPIRE-FH, SPIRE-LDL, SPIRE-1 and SPIRE-2.

1. SPIRE-AI: Pfizer recently announced positive results from Phase 3 SPIRE-AI lipid-lowering study evaluating Bococizumab. It was a 12-week double-blind, placebo-controlled, randomized, parallel-group, multicenter trial on 299 patients with hyperlipidemia receiving statin therapy and with LDLc ≥70 mg/dL. Bococizumab was administered subcutaneously at doses of 75 or 150 mg by auto-injector-prefilled pen device. The end points were percent LDLc reduction at 12 weeks and the success rate of delivery system. The results await publication.

2. SPIRE-FH is a Phase 3, placebo-controlled trial in patients with HeFH which evaluates efficacy of 50 mg Bococizumab given once in 14 days for 12 months and studies percent reduction of LDLc at 12 weeks.

3. SPIRE-HR and SPIRE-LDL are Phase 3 multicenter trials in patients with mixed dyslipidemia and hypercholesterolemia who will receive Bococizumab 150 mg once in 2 weeks for 12 months. Primary end point in both trials is percent change in baseline LDLc at 12 weeks. Secondary end points include changes in total cholesterol, Apo-B, HDLc and triglycerides.

4. SPIRE-SI will evaluate the role of Bococizumab in patients with primary or mixed hyperlipidemia who are intolerant to statin and have high CV risk with LDLc >70 mg/dL and triglyceride ≤400 mg/dL. Primary end point will be percent change in baseline LDLc at 12 weeks.

5. SPIRE-1 and SPIRE-2 are long-term CV outcome studies involving 17,000 patients. SPIRE-2 is fully enrolled. The results are expected in 2018.

Long-term trials with Alirocumab and Evolocumab
Two recent studies presented at ACC-15, ODYSSEY LONG TERM (for Alirocumab) and OSLER-1 and OSLER-2 trials (for Evolocumab), have evaluated the benefits of PCSK9 inhibitors with a longer follow-up duration of ≥52 weeks (Table 5).

Table 5 Long-term trials

<table>
<thead>
<tr>
<th>Trial/study</th>
<th>Reference</th>
<th>Patients</th>
<th>Drug and doses</th>
<th>Mean LDLc reduction</th>
<th>Clinical events</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODYSSEY LONG TERM</td>
<td>Robinson et al36</td>
<td>Number</td>
<td>Alirocumab 75–150 mg biweekly Duration 78 weeks</td>
<td>Group</td>
<td>Basal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2,341</td>
<td>Control 1,553</td>
<td>Control 121.9 mg/dl</td>
<td>122.6 mg/dl</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alirocumab 75–150 mg biweekly Duration 78 weeks</td>
<td>Alirocumab 0.95%</td>
<td>Reduction 48.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Control 788</td>
<td>HeFH 247</td>
<td>120 mg/dl</td>
</tr>
<tr>
<td>COMBINED OSLER-1 and</td>
<td>Sabatine et al41</td>
<td>Number</td>
<td>Evolocumab 140 mg biweekly or 420 mg monthly</td>
<td>Group Reduction 52.8% (P &lt; 0.001)</td>
<td>Basal</td>
</tr>
<tr>
<td>OSLER-2</td>
<td></td>
<td>4,465</td>
<td>Duration 11.1 months</td>
<td>Control 121 mg/dl</td>
<td>120 mg/dl</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Evolocumab 120 mg/dl</td>
<td>Evolocumab 0.95%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reduction 61% (P &lt; 0.01)</td>
<td>Reduction 56.4%</td>
</tr>
</tbody>
</table>

Abbreviations: LDLc, low-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia.
ODESSEY LONG TERM trial

The ODESSEY LONG TERM trial included 2,341 high-risk patients with LDLc >70 mg/dL. The baseline mean LDLc in Alirocumab group was 122.7±24.6 mg/dL, while in placebo group, it was 121.9±41.4 mg/dL. The LDLc at 24 and 48 weeks in Alirocumab vs placebo groups was 48.3 and 57.9 vs 118.9 and 122.6 mg/dL. At week 24, the difference between Alirocumab and placebo groups in the mean percent change from baseline was 62% points (P<0.001), and reduction in LDLc persisted throughout 78 weeks of follow-up. There was also a significant reduction in the levels of non-HDLc, Apo-B, total cholesterol, Lp (a) and fasting triglyceride with a mild increase in HDLc and Apo-A. The clinical event outcomes (reduction in death from CV causes, nonfatal myocardial infarction and unstable angina) were compared between the two groups in a post hoc analysis which showed ~50% reduction of adverse clinical outcomes with Alirocumab vs placebo (1.7% vs 3.3%, hazard ratio 0.52, 95% CI 0.31–0.90, P=0.02). The Alirocumab group as compared with placebo group had a higher rate of injection-site reaction (5.9% vs 4.2%), myalgia (5.4% vs 2.9%), neurocognitive events such as amnesia, memory impairment and confusion (1.2% vs 0.5%) and ophthalmic events (2.9% vs 1.9%). The authors concluded that Alirocumab when added to statin therapy at the maximum tolerated dose significantly reduced LDLc and the rate of CV events was also reduced.

OSLER-1 and OSLER-2

This study enrolled 4,465 patients which included 2,976 patients as Evolocumab group and 1,489 patients as placebo-standard therapy group. The patients were followed for ~11 months with periodic assessment of lipid levels, safety and adjusted CV events. Mean LDLc at baseline in Evolocumab and standard therapy groups was 120 (97–149) and 121 (97–151) mg/dL, respectively. After 11.1 months, Evolocumab reduced LDLc from a mean of 120 to 48 mg/dL (P<0.001), while there was no significant change in LDLc in standard therapy group (121–120 mg/dL). Thus, the reduction in LDLc by Evolocumab was by 61% (95% CI 59–63, P<0.01). In addition, there was reduction in non-HDLc (~52%), Apo-B (~47.3%), total cholesterol (~36.1%), triglyceride (~12.6%) and mild increase in HDLc (+7%). The rate of CV events (death, myocardial infarction, unstable angina and stroke) at 1 year was reduced from 2.18% in the standard group to 0.95% in Evolocumab group (hazard ratio in Evolocumab group 0.47, 95% CI 0.28–0.78, P=0.003). Most adverse reactions occurred with almost similar frequency in the two groups. The adverse reactions in Evolocumab vs standard group, respectively, were as follows: serious adverse reactions, 222 (7.5%) vs 111 (7.5%); muscle related, 190 (6.4%) vs 90 (6.0%); injection-site reaction, 129 (4.3%) vs nil; and neurocognitive events, 27 (0.9%) vs 4 (0.3%). The authors concluded that during 1 year of therapy, Evolocumab significantly reduced LDLc and also the incidence of CV events.

Meta-analysis study

Meta-analysis study of Zhang et al

Twenty-five RCTs encompassing 12,200 patients were included in the study to determine the safety and efficacy of anti-PCSK9 antibodies (Alirocumab and Evolocumab). The primary efficacy end points were the percent and absolute reductions in LDLc and other lipid profile changes at 52 weeks of follow-up. The safety outcomes were the rates of adverse events (Table 6).

The percent LDLc reduction following Evolocumab treatment was 54.6% (95% CI –58.7 to 50.5%) and absolute mean reduction was –78.9 mg/dL (95% CI –88.9 to –68.9 mg/dL) vs placebo and –36.3% (95% CI 38.86–33.9%) vs ezetimibe. HDLc increased by 7.6% (95% CI 5.7–9.5%) vs placebo and

Table 6 Comparison of three meta-analyses on PCSK9 inhibitors

<table>
<thead>
<tr>
<th>Study parameter</th>
<th>Navarese et al41</th>
<th>Zhang et al42</th>
<th>Lipinski et al44</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of trials analyzed</td>
<td>24</td>
<td>25</td>
<td>17</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>10,159</td>
<td>12,200</td>
<td>13,083</td>
</tr>
<tr>
<td>Lipid profile changes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDLc ↓</td>
<td>47.5%</td>
<td>Evolocumab</td>
<td>57%</td>
</tr>
<tr>
<td></td>
<td>Total cholesterol ↓</td>
<td>31.5%</td>
<td>36.6%</td>
</tr>
<tr>
<td>Triglyceride ↓</td>
<td>15.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-HDLc ↓</td>
<td>26.4%</td>
<td>48%</td>
<td>46%</td>
</tr>
<tr>
<td>Lipoproteins ↓</td>
<td>6.3%</td>
<td>7.6%</td>
<td>–</td>
</tr>
<tr>
<td>Rise in HDL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Reduced</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>CV mortality</td>
<td>↓</td>
<td>–</td>
<td>↓</td>
</tr>
<tr>
<td>CV events</td>
<td>↓</td>
<td>–</td>
<td>↓</td>
</tr>
<tr>
<td>Adverse effects of PCSK9 inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe leading to discontinuation of drug</td>
<td>–</td>
<td>1.6–1.9%</td>
<td>–</td>
</tr>
<tr>
<td>Local injection-site reaction and muscle related</td>
<td>1–4%</td>
<td>1.6–2.2%</td>
<td>1–3%</td>
</tr>
<tr>
<td>Neurocognitive effects</td>
<td>1–3%</td>
<td>1.9–3.0%</td>
<td>Increased</td>
</tr>
</tbody>
</table>

Note: “–” indicates data not available.

Abbreviations: PCSK9, proprotein convertase subtilisin/kexin type 9; LDLc, low-density lipoprotein cholesterol; HDL, high-density lipoprotein; CV, cardiovascular.
6.4% (95% CI 4.3–8.4%) vs ezetimibe. Evolocumab generated significant reduction in total cholesterol, non-HDLc and VLDLc.

The efficacy outcome for Alirocumab was on similar lines. LDLc reduced by over 50% (mean reduction −52.6%, 95% CI −58.2 to 47.0%) vs placebo. A less marked reduction of LDLc was found when compared with ezetimibe (−29.9%, 95% CI −32.9 to −26.9%). HDLc level increased by a mean of 8% (95% CI 4.2–11.7%). There was a reduction of total cholesterol, non-HDLc and Apo-B.

Safety outcome judged by common adverse events essentially did not reveal significant differences between anti-PCSK9 antibodies and the placebo (or ezetimibe) except slightly increased rate of injection-site reactions (relative risk 1.48, 95% CI 1.5–2.09, P=0.02). The incidence of TEATs was 52.2% (95% CI 44.8–59.7%) at 12 weeks with PCSK9 antibodies vs 45.2% (95% CI 40.6–49.8%) with placebo. Serious TEATs occurred in 1.9%, leading to discontinuation of treatment with Evolocumab in 1.6% of patients at 12 weeks. Injection-site reactions were slightly more common in patients receiving anti-PCSK9 antibodies. The authors concluded that Evolocumab and Alirocumab were safe, well tolerated and showed no significant differences in rates of adverse events compared with placebo or ezetimibe controls.

Meta-analysis by Navarese et al
Navarese et al\(^ {14} \) evaluated 24 trials (eight, Phase 2; 16, Phase 3 trials) comprising 10,159 patients. Most trials were short (<6 months: 17 trials). Duration was 6–12 months in two trials, and over 1 year in five trials. Efficacy of PCSK9 antibodies was based on 1) correction of lipid profile, 2) clinical outcome in terms of mortality and 3) incidence of adverse events.

1. There was a reduction of LDLc by 47.49% (95% CI −69.64 to −25.235%, P<0.001) with a larger reduction when compared with placebo (−58.77%, 95% CI 56.5–61.5%) than when compared with ezetimibe (−36.17%, 95% CI 33.1–39.3%). There was reduction in total cholesterol by 31.9% and in lipoprotein by 26.4% and increase in HDLc (14 trials) by 6.3%.

2. Use of PCSK9 antibodies was associated with a significant reduction in all-cause mortality rate (0.31% in anti-PCSK-treated group vs 0.53% in placebo group; OR 0.45, 95% CI 0.23–0.86, P=0.015); all-cause mortality was reduced by 41.5% by PCSK9 inhibitors when compared with placebo.

3. A statistically nonsignificant reduction in CV mortality was observed with PCSK9 inhibitors (0.19%) vs placebo (0.33%) (OR 0.50, 95% CI 0.23–1.1, P=0.84). In addition, there was a significant reduction of secondary safety end point myocardial infarction vs placebo (OR 0.49, 95% CI 0.26–0.93, P=0.03).

4. The overall incidence of serious adverse events and the rate of discontinuation of therapy were similar in the two groups.

The authors concluded that their meta-analysis provides preliminary data on long-term efficacy and clinical outcome. However, their findings need further confirmation with prospective CVOTs which are being pursued currently.

Meta-analysis of Lipinski et al
Lipinski et al\(^ {44} \) have meta-analyzed a total of 17 trials involving 13,083 patients (8,250 given PCSK9 inhibitors, 846 given ezetimibe and 3,987 placebo).

1. PCSK9 inhibition alone led to 57% lower LDLc, 36% lower total cholesterol, 46% lower Apo-B, 24.3% lower Lp (a) and 47% lower PCSK9 levels. Compared with placebo, PCSK9 and ezetimibe resulted in reduction of LDLc by 69% and 21%, respectively. Maximum reduction of LDLc of 57.8% was seen when PCSK9 inhibitors were given in patients with high baseline statin therapy (from basal level of 122 to 51 mg/dL). Many trials found at least one LDLc value as low as 25 mg/dL.

2. All-cause mortality was reduced significantly (hazard ratio 0.43, 95% CI 0.27–0.48, P=0.01).

3. CV mortality was reduced but not significantly (hazard ratio 0.50, 95% CI 0.23–1.13, P=0.10).

4. CV events were reduced but not significantly (hazard ratio 0.67, 95% CI 0.43–1.04, P=0.07).

5. Adverse events: neurocognitive events were increased with PCSK9 inhibitors (hazard ratio 2.31, 95% CI 1.11–4.93, P=0.01).

The authors concluded that PCSK9 inhibitors significantly improve lipid profile and reduce all-cause mortality but are associated with increased neurocognitive events. The authors suggested adjusting the dose of PCSK9 inhibitors to keep LDLc in the range of 50–70 mg/dL.

To summarize, PCSK9 inhibitors decreased LDLc effectively to an extent of ≥50% in all three meta-analyses. Navarese et al and Lipinski et al showed a significant reduction in all-cause mortality by PCSK9 inhibitors. There was a trend toward reduction in CV events. Zhang et al evaluated the safety outcome and the rates of adverse reactions. They found that PCSK9 inhibitors are safe and well tolerated. Local injection-site reactions, nasopharyngitis and mild
vascular Health and risk management

2. Number of patients need to be treated for 5 years to avoid
1. Use of PCSK9 inhibitors substantially reduces nonfatal

As of today, PCSK9 inhibitors are not cost-effective in the UK for FH patients. However, for secondary prevention, the cost could be $2,400–2,700 per year. The incremental cost was assessed and compared against total major adverse CV events averted (and money saved) and QALY gained. The important findings of the ICER draft report45 on PCSK9 inhibitors are summarized as follows:

1. Use of PCSK9 inhibitors substantially reduces nonfatal myocardial infarction, nonfatal stroke and CV deaths over ≥5 years.
2. Number of patients need to be treated for 5 years to avoid one major fatal CV event appears to be in favor of PCSK9 inhibitors.
3. Draft ICER (2015)45 value-based price benchmark for PCSK9 inhibitors works out to be $2,177 per year. Hence, the present cost of $14,600 or $14,100 should be reduced by 85%. As of today, PCSK9 inhibitors are not cost-effective and will put extra burden on the government/insurance corporate.
4. Using a “willingness to pay” threshold of $50,000 per QALY gained, PCSK9 inhibitors should cost $2,100 per year for FH patients. However, for secondary prevention, the cost could be $2,400–2,700 per year.

Amgen and Sanofi have not agreed with the ICER analysis and feel that the reviewers have not addressed the unmet clinical need of the patients and the draft report of ICER will only create a barrier to the patients who need PCSK9 inhibitors the most. However, high cost will remain a major block in the use of monoclonal antibodies in clinical practice. Hence, there is an unmet need to discover cheaper analogs to inhibit PCSK9.

The cost of PCSK9 inhibitors in the UK is 4,000 sterling pounds ($5,700) for NHS patients. In Europe, the cost is €6,200–7,000.

Indications of PCSK9 inhibitors

PCSK9 inhibitors have been used in patients with FH, severe statin intolerance and non-FH.

Familial hypercholesterolemia

FH is one of the commonest inherited metabolic diseases associated with increased risk of atherosclerosis and early ASCVD. Due to lack of availability of laboratories conducting gene testing, only 10% of FH cases are diagnosed and treated at an early stage. 46

1. HoFH is due to either totally absent or grossly abnormal LDL(R) due to two identical mutations in genes. Fortunately, it is an extremely rare disease. Fasting LDLc is markedly elevated. HoFH presents clinically with marked tendonous xanthomas, premature ASCVD and premature death. Treatment with statins and PCSK9 inhibitors is cost-effective in HoFH for primary and secondary prevention.
2. HeFH is due to single mutation of LDL(R) gene. LDL(R) is defective but not absent. The prevalence of HeFH in Copenhagen general population has been recently estimated as one in 217. 47 This prevalence is based upon Dutch Lipid Clinic Network criteria and estimated LDLc level ≥4.4 mmol/L (165 mg/dL). HeFH is also complicated with early ASVD. The European Atherosclerosis Society Consensus Panel II advises intensive statin therapy when the individuals of HeFH attain the age of 8–12 years. 48 Addition of PCSK9 inhibitors is a viable option if the response of intensive statin therapy is inadequate 49 or when associated with ASCVD.

Statin intolerance

Patients with mild statin intolerance are often managed successfully with reduction of statin dose or change to rosuvastatin from atorvastatin or other brand of statin. However, in severe statin intolerance, this policy may not be successful. PCSK9 inhibitors may be an effective alternative in patients with severe ASCVD with statin intolerance.

Nonfamilial hypercholesterolemia

Non-FH associated with existing ASVD need intensive statin therapy with/without ezetimibe. However, substantial heterogeneity in response to statin therapy has been reported.
in a meta-analysis of eight CV outcomes and the JUPITER TRIAL. The RRR of CV events is proportional to the magnitude of LDLc reduction. In Ridker et al analysis, an RRR of 39% was observed for those with ≤50% LDLc reduction and a relative risk of breast cancer of 59% was observed with ≥59% LDLc reduction. Ridker et al suggested that patients with inadequate LDLc reduction. In Ridker et al analysis, an RRR of 39% was observed for those with ≥50% LDLc reduction by statin therapy may benefit with an additional therapy, for example, ezetimibe or PCSK9 inhibitors. However, PCSK9 inhibitors are costly. Their use may be considered by lipid experts in patients with non-FH with severe existing ASCVD and CV risk ≥10%, depending upon the insurance coverage, national economy and policy of the country.

Number of prescriptions of PCSK9 inhibitors and their refusal by insurance
The exact number of prescriptions of PCSK9 inhibitors and refusal of payment by insurance companies is not known. According to newsletter from the “Frontiers of Health and Medicine” by ED Silverman (April 2016), there were 9,500 prescriptions of Evolocumab and 11,800 prescriptions for Alirocumab with the FDA-approved indications from August 2015 to February 2016 with a refusal rate of 75% by insurance companies.

In a recent study on eligibility for PCSK9 treatment in 734 hypercholesterolemic patients referred to a regional cholesterol center with LDLc ≥70 mg/dL, despite maximally tolerated statin therapy, and based upon the FDA- and insurance-approved eligibility criteria, Glueck et al reported 50 patients approved by an insurance company for PCSK9 therapy. It is believed that insurance companies may be signing some agreement with pharmaceutical companies for value-based or performance-based sharing risks. Amgen has agreed some discount to the NHS (UK), but the exact discount is not disclosed. The NICE, a cost-effectiveness body in the UK, has found Evolocumab cost-effective from the NHS resources and has specified following LDLc levels for use of Evolocumab by the NHS (NICE Draft 2016).

1. HeFH with existing ASCVD: LDLc >3.5 mmol/L (135 mg/dL)
2. HeFH without existing ASCVD: LDLc >4 mmol/L (155 mg/dL)
3. Mixed dyslipidemia without HeFH: LDLc >5 mmol/L (193 mg/dL)

Financial implications
These have remained the hottest topic of debate during 2015–2016.

According to the prevalence rate of HeFH in the USA, total HeFH patients could be more than two million, and the cost of PCSK9 inhibitors for 5 years (or lifelong) would run in several billion dollars.

Kazi et al used Cardiovascular Diseases Policy Model and included adults aged 35–94 years. The simulated model estimated a cost of $423,000 per QALY for PCSK9 inhibitors and a cost of $503,000 per QALY for PCSK9 inhibitors plus statin in patients of HeFH. The US health care cost will increase by $565 billion over 5 years.

The cost of treating a CV event like myocardial infarction includes direct cost of diagnosis and treatment in cardiac institutions and indirect cost of lost work productivity and unemployment, besides mental agony and death. The AHA estimated direct and indirect cost of medical care for ASCVD as $450 billion in 2010. The cost is likely to increase during 2010–2030. Whether, and to what extent, PCSK9 inhibitors will facilitate a reduction in total cost of ASCVD remains to be seen in future. In the meantime, pricey PCKS9 inhibitors require careful patient selection.

Gandra et al have hypothesized that Evolocumab when added to SOC vs SOC alone is cost-effective in patients with HeFH and ASCVD with or without statin intolerance. Treatment was associated with increased cost and improved QALY: 1) for HeFH: incremental cost US$153,289, incremental QALY 2.02 and incremental cost-effectiveness ratio $75,863/QALY; 2) for ASCVD: incremental cost $158,307, incremental QALY 1.2 and incremental cost-effectiveness ratio 141,699/QALY. Thus, Evolocumab met the ACC/AHA and World Health Organization thresholds in this population.

Safety, patient acceptability and adverse events of PCSK9 inhibitors
PCSK9 inhibitors are safe and nontoxic. No life-threatening adverse effects have been reported.

1. Monoclonal antibodies need to be given by subcutaneous injection only. Many patients have injection phobia and never agree to frequent injection for 1–5 years or lifelong. Although painless pen-filled injections are available, the idea of self-injection is not always welcome. Of the total patients, 2–10% develop injection-site reactions. Research for orally active small molecules as PCSK9 inhibitors is under progress by a few pharmaceutical companies (Pfizer, Seromatrix and Bristol-Squibb). Whenever available in future, orally effective analogs of PCSK9 inhibitors will be a welcome addition to anti-lipid drugs.
2. Nonspecific drug-induced adverse events include upper respiratory infections, diarrhea and myalgia in 1–2% of patients.

3. Reactions due to VLDLc (<40 mg/dL).
   - Neurocognitive events include impaired memory, headache and confusion (1–4%). There is no increased incidence of stroke or intracranial hemorrhage.
   - Hormonal insufficiency, especially of adrenal cortex, visceral adiposity and impaired glucose tolerance, has been suspected due to LDLc <25 mg/dL in some patients.

**CV outcome trials**

Reduction in LDLc is often regarded as a surrogate measure of clinical benefits.\(^1\) LDLc reduction was the basis of the FDA approval of statins in 1987. IMPROVE-IT (statin with ezetimibe) study further strengthened this concept.\(^6\) CTT meta-analysis of over 170,000 patients in 26 randomized trials\(^4\) observed a 25% reduction in major vascular events for each 1 mmol/L (38.7 mg/dL) reduction in LDLc by statins. However, ILLUMINATE trial with Torcetrapib\(^56\) and HPS-2 THRIVE trial\(^57\) with Niacin which could lower LDLc were not associated with favorable clinical outcome. Hence, establishing evidence of improved clinical CV outcomes (CVOT) is the key to evaluate new class of medication. The ongoing prospective CVOTs include FOURIER evaluating Evolocumab in 27,500 patients, ODYSSEY OUTCOME evaluating Alirocumab in 18,000 patients and SPIRE-1 and SPIRE-2 evaluating Bococizumab in 17,000 patients (Table 7). The results of CVOT are expected in 2017–2018.

**Conclusion**

Monoclonal antibodies are potent inhibitors of PCSK9 and prevent destruction of LDL(R) with marked reduction of LDLc compared to statin and ezetimibe. A target LDLc of 40–60 mg/dL is possible with PCSK9 inhibitors. Health care benefits with monoclonal antibodies appear substantial in FH (more in HoFH than in HeFH patients). If the relationship between LDLc reduction and clinical benefits is proved in CVOT studies, one can expect 30–40% reduction in vascular events with PCSK9 inhibitors even in patients with non-FH with existing ASCVD and uncontrolled hypercholesterolemia in spite of maximally tolerated statin with or without ezetimibe.

PCSK9 inhibitors are indicated for treatment of FH, and it may be considered cost-effective in HoFH and also HeFH patients with severe existing ASCVD and severe statin intolerance. In non-FH with ASCVD and high CV risk ≥10%, their use will depend upon the economic and national policies of the country in view of their high cost.

**Table 7** Ongoing cardiovascular outcome trials of PCSK9 inhibitors

<table>
<thead>
<tr>
<th>Trial/study</th>
<th>Authority</th>
<th>Patients</th>
<th>Drug</th>
<th>Dose</th>
<th>End points</th>
<th>Follow-up</th>
<th>Results expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOURIER</td>
<td>Clin Trials/Govt/CT2/Show/NCTO 1764633 (2014)</td>
<td>N=27,500</td>
<td>Evolocumab</td>
<td>140 mg biweekly or 420 mg monthly</td>
<td>% fall in LDLc CV death, nonfatal MI, stroke, hospitalization for unstable angina or revascularization</td>
<td>5 years</td>
<td>2017–2018</td>
</tr>
<tr>
<td>ODYSSEY OUTCOME</td>
<td>Clin Trials/Govt/CT2/Show/NCTO 1663402 (2014)</td>
<td>N=18,000</td>
<td>Alirocumab</td>
<td>75–150 mg biweekly</td>
<td>As above</td>
<td>64 months</td>
<td>–</td>
</tr>
<tr>
<td>SPIRE-1</td>
<td>Clin Trials/Govt/CT2/show/NCT 01975376</td>
<td>N=17,000</td>
<td>Bococizumab</td>
<td>150 mg biweekly</td>
<td>As above</td>
<td>60 months</td>
<td>–</td>
</tr>
<tr>
<td>SPIRE-2</td>
<td>Clin Trials/Govt/CT2/show/NCT 01975389</td>
<td>High CV risk LDL ≥100 mg/dl</td>
<td>Bococizumab</td>
<td>150 mg biweekly</td>
<td>As above</td>
<td>60 months</td>
<td>–</td>
</tr>
</tbody>
</table>

**Abbreviations:** PCSK9 proprotein convertase subtilisin/kexin type 9; LDLc, low-density lipoprotein cholesterol; CV, cardiovascular; MI, myocardial infarction; HDL, high-density lipoprotein; TG, triglyceride; Apo-B, apolipoprotein B; LDL, low-density lipoprotein.
Disclosure
The author reports no conflicts of interest in this work.

References